**Table 3:** Relation between Clinical data with lymph node category in study group.

|  |  |  |  |
| --- | --- | --- | --- |
| **Item** | **LN = 0,1,2,3** **"n = 73"** | **LN = 4,5,6** **"n = 30"** | **P-value** |
| 1- |   |   |   |
| IDC | 66 (90.4%) | 26 (86.7%) | P = 0.7, ns |
| Medullary | 3 (4.1%) | 1 (3.3%) |   |
| ILC | 4 (5.5%) | 3 (10%) |   |
|   |   |   |   |
| **2-Grade:** |   |   |   |
| I | 0 | 2 (6.7%) | P = 0.07, ns |
| II | 68 (93.1%) | 27 (90%) |   |
| III | 5 (6.9%) | 1 (3.3%) |   |
|   |   |   |   |
| **1-       Type of surgery:** |   |   |   |
| MRM | 58 (79.5%) | 24 (80%) | P = 0.95, ns |
| BCS | 15 (20.5%) | 6 (20%) |   |
|   |   |   |   |
| **4-T:** |   |   |   |
| X | 3 (4.1%) | 3 (10%) | P = 0.27, ns |
| 1 | 5 (6.9%) | 1 (3.3%) |   |
| 2 | 42 (57.5%) | 21 (70%) |   |
| 3 | 17 (23.3%) | 5 (16.7%) |   |
| 4 | 6 (8.2%) | 0 |   |
|   |   |   |   |
| **6-Extracapsular invasion:** |   |   |   |
| no | 27 (36.9%) | 18 (60%) | P < 0.001\*\* |
| yes | 32 (43.9%) | 2 (6.7%) |   |
| unknown | 14 (19.2%) | 10 (33.3%) |   |
|   |   |   |   |
| **7-ER:** |   |   |   |
| Positive | 48 (65.8%) | 16 (53.3%) | P = 0.36, ns |
| Negative | 24 (32.9%) | 14 (46.7%) |   |
| Unknown | 1 (1.4%) | 0 |   |
|   |   |   |   |
| **8-PR:** | 38 (52.1%) | 15 (50%) | P = 0.8, ns |
| Positive | 34 (46.5%) | 14 (46.7%) |   |
| Negative | 1 (1.4%) | 1 (3.3%) |   |
|   |   |   |   |
| **9- Her2-neu** |   |   |   |
| Positive | 6 (8.2%) | 0 | P = 0.08, ns |
| Negative | 29 (39.7%) | 8 (25.8%) |   |
| Unknown | 38 (52.1%) | 22 (74.2%) |   |
|   |   |   |   |
| **10-Chemotherapy:** |   |   |   |
| CMF | 5 (6.8%) | 2 (6.7%) | P = 0.078, ns |
| FAC | 47 (64.4%) | 14 (46.7%) |   |
| FEC | 14 (19.2%) | 14 (46.7%) |   |
| Taxane based | 3 (4.1%) | 0 |   |
| Herceptin | 1 (1.4%) | 0 |   |
| No CTR | 3 (4.1%) | 0 |   |
|   |   |   |   |
| **11- Radiotherapy:** |   |   |   |
| CW+ PL | 65 (89.4%) | 25 (83.3%) | P = 0.203, ns |
| CW | 3 (4.1%) | 4 (13.3%) |   |
| no Rth | 5 (6.8%) | 1 (3.3%) |   |
|   |   |   |   |
| **12-Hormonal treatment:** |   |   |   |
| Tam | 40 (54.8%) | 15 (50%) | P = 0.564, ns |
| AIs | 10 (13.7%) | 2 (6.6%) |   |
| Not given | 22 (30.1%) | 12 (40%) |   |
| Tam and Zoladex | 1 (1.4%) | 1 (3.3%) |   |